MediGene Polyphenon E Phase III data

MediGene (FSE:MDG) said in a double-blind placebo-controlled, international Phase III trial in more

Read the full 133 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE